The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mediastinoscopy


High impact information on Mediastinoscopy

  • RESULTS: EGFR expression determined on 138 of 164 patients who underwent mediastinoscopy or mediastinostomy was 0 (22 patients), 1+ (27 patients), 2+ (28 patients), and 3+ (61 patients) [6].
  • In T2 and T3 patients, the ICER of routine mediastinoscopy was more favorable ($42,800 and $53,400 per QALY gained, respectively) [7].
  • PATIENTS AND METHODS: Following staging, including mediastinoscopy, 94 patients with inoperable LAD-NSCLC were treated preoperatively with chemotherapy (three courses of split-dose cisplatin and etoposide [PE]) followed by concurrent chemoradiotherapy (one course of PE combined with 45 Gy hyperfractionated accelerated radiotherapy) [8].
  • PATIENTS AND METHODS: Thirty-nine patients with mediastinoscopy stage IIIA N2 NSCLC received two cycles of MVP [9].
  • Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction [10].

Chemical compound and disease context of Mediastinoscopy


Anatomical context of Mediastinoscopy


Associations of Mediastinoscopy with chemical compounds


Gene context of Mediastinoscopy

  • Mediastinoscopy is indicated in patients with serum CEA concentrations > or = 5.0 ng/mL and maximum tumor dimension > or = 20 mm, and not indicated in patients with serum CEA concentrations < 5.0 ng/mL and maximum tumor dimension < 20 mm [16].
  • CONCLUSION: It was concluded that evaluation of CEA in addition to CT is of use in the diagnosis of N2 disease in NSCLC patients and should be used as an indication for mediastinoscopy [17].
  • Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients [18].
  • Thirty-four patients with an aortic window lesion were carefully staged with gallium scans and mediastinoscopy according to the TNM classification system for carcinoma of the lung [19].
  • All patients underwent pretreatment evaluation at the university's Multidisciplinary Lung Cancer Center. Most patients (87%) had complete mediastinoscopy staging, and all were believed to be poor candidates for up-front operation because of bulky extent of disease [20].

Analytical, diagnostic and therapeutic context of Mediastinoscopy


  1. Thoracic lymphadenopathy in Asians resident in the United Kingdom: role of mediastinoscopy in initial diagnosis. Farrow, P.R., Jones, D.A., Stanley, P.J., Bailey, J.S., Wales, J.M., Cookson, J.B. Thorax (1985) [Pubmed]
  2. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Eberhardt, W., Stamatis, G., Stuschke, M., Wilke, H., Müller, M.R., Kolks, S., Flasshove, M., Schütte, J., Stahl, M., Schlenger, L., Budach, V., Greschuchna, D., Stüben, G., Teschler, H., Sack, H., Seeber, S. Br. J. Cancer (1999) [Pubmed]
  3. Induction chemotherapy for stage IIIA unresectable non-small cell lung cancer: the Toronto experience and an overview. Goldberg, M., Burkes, R.L. Seminars in surgical oncology. (1993) [Pubmed]
  4. Mediastinoscopy: a diagnostic aid in metastatic carcinoma of the breast. Neifeld, J.P., Ingle, J.N., Tormey, D.C., Lippman, M.E., Richman, S.D., Michaelis, L.L. Cancer (1976) [Pubmed]
  5. Computed tomography and the TNM classification of lung cancer. Sparup, J., Friis, M., Brenøe, J., Vejlsted, H., Villumsen, B., Olesen, K.P., Borgeskov, S., Bertelsen, S. Scandinavian journal of thoracic and cardiovascular surgery. (1990) [Pubmed]
  6. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. De Pas, T., Pelosi, G., de Braud, F., Veronesi, G., Curigliano, G., Leon, M.E., Danesi, R., Noberasco, C., d'Aiuto, M., Catalano, G., Viale, G., Spaggiari, L. J. Clin. Oncol. (2004) [Pubmed]
  7. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. Esnaola, N.F., Lazarides, S.N., Mentzer, S.J., Kuntz, K.M. J. Clin. Oncol. (2002) [Pubmed]
  8. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. Eberhardt, W., Wilke, H., Stamatis, G., Stuschke, M., Harstrick, A., Menker, H., Krause, B., Müeller, M.R., Stahl, M., Flasshove, M., Budach, V., Greschuchna, D., Konietzko, N., Sack, H., Seeber, S. J. Clin. Oncol. (1998) [Pubmed]
  9. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. Burkes, R.L., Ginsberg, R.J., Shepherd, F.A., Blackstein, M.E., Goldberg, M.E., Waters, P.F., Patterson, G.A., Todd, T., Pearson, F.G., Cooper, J.D. J. Clin. Oncol. (1992) [Pubmed]
  10. Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Dosios, T., Theakos, N., Chatziantoniou, C. Chest (2005) [Pubmed]
  11. A pitfall with the use of 111In-pentetreotide scintigraphy in the resected bronchopulmonary carcinoids follow-up: a case report. Grazia, M., Ansaloni, L., Bini, A., Grani, G., Mastrorilli, M., Pagani, D., Sellitri, F., Stella, F., Bazzocchi, R. Acta chirurgica Hungarica. (1999) [Pubmed]
  12. Comparative evaluation of technetium-99m glucoheptonate and gallium-67 citrate thoracic imaging in detection of mediastinal and hilar involvement in primary lung cancer. Taillefer, R., Beauchamp, G., Léveillé, J. Clinical nuclear medicine. (1986) [Pubmed]
  13. Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy. Lee, J.D., Ginsberg, R.J. Ann. Thorac. Surg. (1996) [Pubmed]
  14. Use and prognostic value of staging mediastinoscopy in non-small-cell lung cancer. Albertucci, M., DeMeester, T.R., Golomb, H.M., MacMahon, H.K., Ryan, J.W., Iascone, C. Surgery (1987) [Pubmed]
  15. Surgical treatment of neuroendocrine tumors of the lung. Daddi, N., Ferolla, P., Urbani, M., Semeraro, A., Avenia, N., Ribacchi, R., Puma, F., Daddi, G. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. (2004) [Pubmed]
  16. Clinical predictors of N2 disease in non-small cell lung cancer. Takamochi, K., Nagai, K., Suzuki, K., Yoshida, J., Ohde, Y., Nishiwaki, Y. Chest (2000) [Pubmed]
  17. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer. Ando, S., Kimura, H., Iwai, N., Kakizawa, K., Shima, M., Ando, M. Respirology (2003) [Pubmed]
  18. Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients. Mineo, T.C., Ambrogi, V., Nofroni, I., Pistolese, C. Ann. Thorac. Surg. (1999) [Pubmed]
  19. Bronchogenic carcinoma located in the aortic window. The importance of the primary lesion as a determinant of survival. Levett, J.M., Darakjian, H.E., DeMeester, T.R., Golomb, H.M., Kirchner, P.T., Lu, C., MacMahon, H., Gordon, L.I., Sternberg, P. J. Thorac. Cardiovasc. Surg. (1982) [Pubmed]
  20. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. Machtay, M., Lee, J.H., Stevenson, J.P., Shrager, J.B., Algazy, K.M., Treat, J., Kaiser, L.R. J. Thorac. Cardiovasc. Surg. (2004) [Pubmed]
  21. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer. Harper, P. Semin. Oncol. (1997) [Pubmed]
  22. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Stamatis, G., Eberhardt, W., Stüben, G., Bildat, S., Dahler, O., Hillejan, L. Ann. Thorac. Surg. (1999) [Pubmed]
  23. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Burkes, R.L., Shepherd, F.A., Blackstein, M.E., Goldberg, M.E., Waters, P.F., Patterson, G.A., Todd, T., Pearson, F.G., Jones, D., Farooq, S., McGlaughlin, J., Ginsberg, R.J. Lung Cancer (2005) [Pubmed]
WikiGenes - Universities